As a leader in the design and delivery of care-based, oncology research, George Clinical has access to significant global investigator networks, experienced project teams, oncology experts, and scientific leaders to design and deliver oncology trials, with the latest immunotherapies, to the highest scientific standards. By accessing some of the world’s most experienced medical, scientific and operational teams in oncology research, George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research, and thus demonstrates product value in terms of clinical effectiveness, specialized cohorts and tolerability.
Exceptional medical, scientific and operational expertise makes George Clinical an ideal partner for clinical trials throughout North America, Europe and the Asia-Pacific.
George Clinical has extensive experience in all phases of oncology programs including, MTD, early Phase I, II and III and late-phase trials, health economics and outcomes research. Our full services team is comprised of scientific leaders, doctors, nurses, biostatisticians and trial management professionals that work together to ensure timely delivery of quality trial data on time and on budget.
George Clinical offers a unique combination of scientific leadership and operational capabilities to design and deliver studies for sponsors, no matter the complexity. George Clinical offers:
George Clinical’s extensive experience in oncology trials provides sponsors with the confidence that their oncology trial will be delivered on time, on budget and to the highest scientific standards.
Our clinical trial services in oncology clinical trials include:
Susan is responsible for U.S. project and clinical operations, including project management, study startup, monitoring and site management services. With over 25 years in clinical research, she brings experience in all phases of clinical trials, multiple therapeutic areas including over 12 years in oncology, and key leadership roles in clinical operations and financial management. She has helped develop or improve services for multiple U.S. Contract Research and Site Management organizations, as well as a national oncology site network. Her work with global and cross-functional teams brings added value to the George Clinical team.
Dr. Schwartzberg’s research interests include breast cancer, supportive care and developmental therapeutics. He is the Chief Medical Director of West Cancer Center and Chief of the Division of Hematology/Oncology at the University of Tennessee Health Science Center. In addition, he was appointed by the partnership, OneOncology, to Chief Medical Officer. He was recently involved with genomic profiling of advanced cancer and is interested in visionary approaches to clinical research and oncology science. He divides his time between patients in the clinic and conducting clinical research trials and programmatic development.
A renowned expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg is a member of the Board of Directors for the National Comprehensive Cancer Network and is the founding editor-in-chief of the journal Community Oncology. He is also the current editor-in-chief of the Practice Update Oncology website and serves on the editorial board for both the Journal of Supportive Oncology and the ASCO Post.
Dr. Boccia’s research interest is in cancers of the blood and blood-forming tissues as well as solid tumors, such as those seen in bladder cancer. He is Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Maryland, and Clinical Associate Professor of Medicine at Georgetown University in Washington, DC. He also serves as the Chief Medical Officer for the International Oncology Network (ION). He conducts research in exploring the latest advances in colorectal cancer treatment and offers individualized care to patients with focus on multi-modal treatment regimens.
Dr. Boccia has studied and published cancer patients’ supportive care data on cytokine support for chemotherapy-induced anemia and leukopenia, and cytoprotective agents; specifically, amifostine (Ethyol) administration schedules designed to reduce side effects and improve safety. He is a member of numerous professional societies including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation.
Dr. VanderWalde’s research interests include immune therapies in solid tumors and melanoma. He is Director of Research at West Cancer Center; Senior Medical Director at George Clinical; and Medical Director of Precision Medicine at OneOncology. He has collaborated and participated on advisory board with many of the nation’s thought leaders and top experts in the field and previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunitherapeutic that has shown efficacy in late-stage clinical trials in melanoma.
As Director of Research at West Cancer Center, Dr. VanderWalde is responsible for managing the portfolio of all clinical trials at the Cancer Center. He also serves as Medical Director of the Clinical Trials Network of Tennessee. He has been involved in research targeting therapy in a more personalized fashion based on immune markers and aberrations in cancer genetics.
Dr. Loong’s clinical interests include sarcoma medical oncology, neuro-oncology, thoracic oncology and experimental therapeutics (Phase I clinical trials). He is based in Hong Kong and holds conjoint appointments of Clinical Assistant Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase I Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. He has conducted over 50 oncology Phase I, II and III trials as either a Principal Investigator or Co-Investigator and is interested in actively helping to develop further capacity for oncology research within the APAC region.
Dr. Loong obtained his medical degree from The University of Hong Kong and completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a special focus on Experimental Therapeutics. He is a recipient of the European Cancer Congress Fellowship Grant (2013), the ASCO Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers, Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.
Dr. Pluard’s research is focused on new targeted therapies of breast cancer. He is Medical Director, Saint Luke’s Cancer Institute and Koontz Center for Advanced Breast Cancer, Kansas City, MO. Previously, he was Associate Professor of Medicine and Clinical Director of Breast Oncology at Washington University Siteman Cancer Center in St. Louis. He specializes in offering comprehensive care including advanced genomic and immunotherapy treatments to women with metastatic breast cancer and advises patients on participating in clinical trials for leading-edge treatments.
Dr. Pluard leads a team at St. Luke’s Cancer Institute focused on the comprehensive care of women with breast cancer where every woman’s tumor is genetically analyzed to understand what is driving their cancer. He emphasizes the importance of in-depth communication with patients taking a fully holistic approach to their treatment options. With his work at Saint Luke’s, Koontz Center and in clinical trials, Dr. Pluard strives to help define care for all women with advanced breast cancer.
Her research is focused on lymphoproliferative disorders and the cellular origin of lymphoma. She is Senior Consultant in Clinical and Laboratory Hematology at Canberra Hospital and Associate Professor at the Australian National University. She is also a long-standing member of Myeloma Australia’s Medical and Scientific Advisor Group, as well as other leading cancer trial and research groups. Working between diagnostic clinical hematology and lab-based research has allowed her to develop molecular assays and translate them into clinical use
Dr. Talaulikar contributes to medical workforce development and advocacy for equity of access to diagnostic tests and blood cancer treatments through leadership roles in organizations such as Royal College of Pathologists of Australasia (RCPA), National Blood Authority and Myeloma Australia. She is recognized as a key opinion leader (KOL) and is regularly invited to participate in Advisory Boards of pharmaceutical companies to provide guidance into clinical development of drugs, feedback into trial protocols and insights into research opportunities. She has authored both national and international clinical practice guidelines that have had a significant impact on cancer patient care. She has also served as Principal Investigator and Co-Investigator of several lymphoma, leukemia and myeloma trials.
Dr. Chandler specializes in medical oncology, hematology and blood cancers. He is Director of Research for Hematology Malignancies at West Cancer Center. Dr. Chandler was a co-leader in the efforts to gain FDA approval for the delivery of CAR-T therapy to cancer patients in 2019, paving the way for CAR-T therapies and treatments to be tested across the country. He is interested in research and immunology and committed to providing patients with access to early-stage clinical trials.